
|Articles|November 15, 2002
Once-daily glaucoma therapy better tolerated than b.i.d.
Houston-In patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH), once-daily treatment with fixed-combination latanoprost/timolol (Xalacom, Pharmacia, Peapack, NJ) is well tolerated and lowers IOP more effectively than twice-daily dorzolamide/timolol (Cosopt, Merck), according to a recent multicenter U.S. study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA update: Outlook Therapeutics receives CRL for resubmitted ONS-5010 BLA
2
What changed in glaucoma care in 2025: Surgeon perspective
3
Inside the clinic: Surgeon shares real-world experience
4
Achieving a new level of refractive precision: Surgical strategies
5












































